ÆÄÀÌÇÁ¶óÀÎ ºÐ¼® ½ÃÀåÁ¶»çº¸°í¼­

ÆÄÀÌÇÁ¶óÀÎ ºÐ¼® ½ÃÀåÀ» Á¶»ç ºÐ¼®ÇÑ ÀÚ·á·Î ½ÃÀå±Ô¸ð, »ê¾÷ºÐ¼®, ÇâÈÄ ½ÃÀå¿¹Ãø µîÀÇ ³»¿ëÀ» ´Ù·ç°í ÀÖ½À´Ï´Ù.

1 - 25 (Àüü: 527°Ç)
¼¼°èÀÇ SGLT2 ¾ïÁ¦Á¦ ½ÃÀå : »ê¾÷±Ô¸ð, Á¡À¯À², µ¿Çâ, ±âȸ, ¿¹Ãø, ¾àÁ¦º°, ÀûÀÀÁõº°, Áö¿ªº°, °æÀﺰ(2020-2030³â)
SGLT2 Inhibitors Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug (Jardiance, Farmiga, Inpefa, Invokana, Others), By Indication (Type 2 Diabetes, Cardiovascular, Others), By Region and Competition, 2020-2030F
¹ßÇà 2025³â 08¿ù
°¡°Ý US $ 4,500 £Ü 6,322,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ Å¸¾×·ç Ä¡·á ½ÃÀå
Sialorrhea Treatment
¹ßÇà 2025³â 08¿ù
°¡°Ý US $ 5,850 £Ü 8,218,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ Áø¼ºÀûÇ÷±¸Áõ°¡Áõ Ä¡·áÁ¦ ½ÃÀå
Polycythemia Vera Drugs
¹ßÇà 2025³â 08¿ù
°¡°Ý US $ 5,850 £Ü 8,218,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ ºñ°áÇÙ¼ºÇ×»ê±ÕÁõ ½ÃÀå
Nontuberculous Mycobacterial Infections
¹ßÇà 2025³â 08¿ù
°¡°Ý US $ 5,850 £Ü 8,218,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ ´Ù°èÅë À§ÃàÁõ ½ÃÀå
Multiple System Atrophy
¹ßÇà 2025³â 08¿ù
°¡°Ý US $ 5,850 £Ü 8,218,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ Èí¼öºÒ·®ÁõÈıº ½ÃÀå
Malabsorption Syndrome
¹ßÇà 2025³â 08¿ù
°¡°Ý US $ 5,850 £Ü 8,218,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ ¾î¼Å ÁõÈıº Ä¡·á ½ÃÀå
Usher Syndrome Treatment
¹ßÇà 2025³â 08¿ù
°¡°Ý US $ 5,850 £Ü 8,218,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ Àü½Å¼º ¼Ò¾ÆÆ¯¹ß¼º°üÀý¿° ½ÃÀå
Systemic Juvenile Idiopathic Arthritis
¹ßÇà 2025³â 08¿ù
°¡°Ý US $ 5,850 £Ü 8,218,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ ÀÌÁú±Õ °Ë»ç ŰƮ ½ÃÀå
Shigella Test Kits
¹ßÇà 2025³â 08¿ù
°¡°Ý US $ 5,850 £Ü 8,218,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ Å¥¿­ ½ÃÀå
Q Fever
¹ßÇà 2025³â 08¿ù
°¡°Ý US $ 5,850 £Ü 8,218,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ Æä´Ò¾Ë¶ó´Ñ ½ÃÀå
Phenylalanine
¹ßÇà 2025³â 08¿ù
°¡°Ý US $ 5,850 £Ü 8,218,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ ÀûÇ÷±¸Áõ°¡Áõ ½ÃÀå
Polycythemia
¹ßÇà 2025³â 08¿ù
°¡°Ý US $ 5,850 £Ü 8,218,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ µ¿ÇüÁ¢ÇÕ °¡Á·¼º °íÄÝ·¹½ºÅ×·ÑÇ÷Áõ ½ÃÀå
Homozygous Familial Hypercholesterolemia
¹ßÇà 2025³â 08¿ù
°¡°Ý US $ 5,850 £Ü 8,218,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ SGLT2 ¾ïÁ¦Á¦ ½ÃÀå
SGLT2 Inhibitors
¹ßÇà 2025³â 08¿ù
°¡°Ý US $ 5,850 £Ü 8,218,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ ¸ÞÆ¿¾Ë·ç¹Ì³ì»ê MAO ½ÃÀå º¸°í¼­ : µ¿Çâ, ¿¹Ãø ¹× °æÀï ºÐ¼®(-2031³â)
Methylaluminoxane MAO Market Report: Trends, Forecast and Competitive Analysis to 2031
¹ßÇà 2025³â 08¿ù
°¡°Ý US $ 3,850 £Ü 5,408,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ µðÆéƼµô ÆéƼ´Ù¾ÆÁ¦ 4 ¾ïÁ¦Á¦ ½ÃÀå
Dipeptidyl Peptidase 4 Inhibitors
¹ßÇà 2025³â 08¿ù
°¡°Ý US $ 5,850 £Ü 8,218,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ ¸»´Üºñ´ëÁõ Ä¡·á ½ÃÀå
Acromegaly Treatment
¹ßÇà 2025³â 08¿ù
°¡°Ý US $ 5,850 £Ü 8,218,000 (ºÎ°¡¼¼ º°µµ)
¸»·¹À̽þÆÀÇ µ¥ÀÌÅͼ¾ÅÍ ºÕÀº º®¿¡ ºÎµúÃÆ´Â°¡?
Has Malaysia's Datacenter Boom Hit a Wall?
¹ßÇà 2025³â 08¿ù
°¡°Ý US $ 7,500 £Ü 10,536,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ ³ì³ó±Õ °¨¿°Áõ Ä¡·á ½ÃÀå
Pseudomonas Aeruginosa Infection Treatment
¹ßÇà 2025³â 08¿ù
°¡°Ý US $ 5,850 £Ü 8,218,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ Æ¯¹ß¼º Ç÷¼ÒÆÇ °¨¼Ò¼º ÀÚ¹ÝÁõ Ä¡·áÁ¦ ½ÃÀå
Idiopathic Thrombocytopenic Purpura Therapeutics
¹ßÇà 2025³â 08¿ù
°¡°Ý US $ 5,850 £Ü 8,218,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ ±Û·çÄ«°ï ½ÃÀå
Glucagon
¹ßÇà 2025³â 07¿ù
°¡°Ý US $ 5,850 £Ü 8,218,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ ¼±Ãµ¼º °íÀν¶¸°Ç÷Áõ Ä¡·á ½ÃÀå
Congenital Hyperinsulinism Treatment
¹ßÇà 2025³â 07¿ù
°¡°Ý US $ 5,850 £Ü 8,218,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ º¹ÇÕºÎÀ§ ÅëÁõ ÁõÈıº ½ÃÀå
Complex Regional Pain Syndrome
¹ßÇà 2025³â 07¿ù
°¡°Ý US $ 5,850 £Ü 8,218,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ GLP-1 À¯»çü ½ÃÀå : ÀûÀÀÁõº°, ¿ëµµº°, À¯Åë ä³Îº°, Áö¿ªº° - ±âȸ ¹× ¿¹Ãø(2018-2032³â)
Global GLP-1 Analogues Market Assessment, By Indication, By Application, By Distribution Channel, By Region, Opportunities and Forecast, 2018-2032F
¹ßÇà 2025³â 07¿ù
°¡°Ý US $ 4,800 £Ü 6,743,000 (ºÎ°¡¼¼ º°µµ)
¼¼°èÀÇ ¾Ëµµ½ºÅ×·Ð ÇÕ¼ºÈ¿¼Ò ¾ïÁ¦Á¦ ½ÃÀå : ¾àÁ¦ À¯Çüº°, ¾à¹°º°, ÀûÀÀÁõº°, °³¹ß ´Ü°èº°, ¼ºº°, ÃÖÁ¾ »ç¿ëÀÚº°, Áö¿ªº°(2025-2032³â)
Aldosterone Synthase Inhibitors Market, By Drug Type, By Drug, By Indication, By Stage of Development, By Gender, By End User, By Geography
¹ßÇà 2025³â 07¿ù
°¡°Ý US $ 4,500 £Ü 6,322,000 (ºÎ°¡¼¼ º°µµ)
(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.